Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout

Arthritis and Rheumatology

Volumn 66, Issue 5, 2014, Pages 1327-1339

  Holzinger, Dirk ^a   Nippe, Nadine ^a   Vogl, Thomas ^a   Marketon, Kristina ^a   Mysore, Vijayashree ^a   Weinhage, Toni ^a   Dalbeth, Nicola ^b   Pool, Bregina ^b   Merriman, Tony ^c   Baeten, Dominique ^d   Ives, Annette ^e   Busso, Nathalie ^e   Foell, Dirk ^a   Bas, Sylvette ^f   Gabay, Cem ^f   Roth, Johannes ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e NESTLÉ RESEARCH CENTER   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; URATE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOUT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PERITONEAL EXUDATE CELL; PERITONITIS; PHAGOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYNOVIAL FLUID LEVEL; SYNOVIUM; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CALGRANULIN A; CALGRANULIN B; CELLS, CULTURED; CRYSTALLIZATION; DISEASE MODELS, ANIMAL; FEMALE; GOUT; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PHAGOCYTES; TOLL-LIKE RECEPTOR 4; URIC ACID;

EID: 84899745315     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38369     Document Type: Article

References (50)

1. Terkeltaub R,. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6: 30-8.
2. Di Giovine FS, Malawista SE, Nuki G, Duff GW,. Interleukin 1 (IL 1) as a mediator of crystal arthritis: stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987; 138: 3213-8.
3. Di Giovine FS, Malawista SE, Thornton E, Duff GW,. Urate crystals stimulate production of tumor necrosis factor α from human blood monocytes and synovial cells: cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991; 87: 1375-81.
4. Guerne PA, Terkeltaub R, Zuraw B, Lotz M,. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32: 1443-52.
5. Schiltz C, Liote F, Prudhommeaux F, Meunier A, Champy R, Callebert J, et al. Monosodium urate monohydrate crystal- induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum 2002; 46: 1643-50.
6. Shi Y, Evans JE, Rock KL,. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
7. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J,. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
8. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD,. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-5.
9. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J,. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-25.
10. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62: 3064-76.
11. So A, De Smedt T, Revaz S, Tschopp J,. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.
12. Fenton MJ,. Review: transcriptional and post-transcriptional regulation of interleukin 1 gene expression. Int J Immunopharmacol 1992; 14: 401-11.
13. Martinon F, Mayor A, Tschopp J,. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65.
14. Tschopp J, Schroder K,. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010; 10: 210-5.
15. Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116: 2262-71.
16. Martinon F, Burns K, Tschopp J,. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell 2002; 10: 417-26.
17. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, van der Ven J, Kullberg BJ, Netea MG, et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1β by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 2009; 68: 273-8.
18. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9.
19. Sampson B, Fagerhol MK, Sunderkotter C, Golden BE, Richmond P, Klein N, et al. Hyperzincaemia and hypercalprotectinaemia: a new disorder of zinc metabolism. Lancet 2002; 360: 1742-5.
20. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular- onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 628-37.
21. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C,. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272: 9496-502.
22. Roth J, Vogl T, Sorg C, Sunderkotter C,. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003; 24: 155-8.
23. Viemann D, Strey A, Janning A, Jurk K, Klimmek K, Vogl T, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005; 105: 2955-62.
24. Newton RA, Hogg N,. The human S100 protein MRP-14 is a novel activator of the β2 integrin Mac-1 on neutrophils. J Immunol 1998; 160: 1427-35.
25. + T cells. Nat Med 2010; 16: 713-7.
26. Van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008; 67: 1750-8.
27. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004; 104: 4260-8.
28. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303: 1266-73.
29. Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71: 974-80.
30. Wittkowski H, Kuemmerle-Deschner JB, Austermann J, Holzinger D, Goldbach-Mansky R, Gramlich K, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis 2011; 70: 2075-81.
31. Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van Damme N, De Vos M, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002; 196: 343-50.
32. Roth J, Burwinkel F, van den Bos C, Goebeler M, Vollmer E, Sorg C,. MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. Blood 1993; 82: 1875-83.
33. Dalbeth N, Pool B, Gamble GD, Smith T, Callon KE, McQueen FM, et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 2010; 62: 1549-56.
34. Palmer DG, Hogg N, Denholm I, Allen CA, Highton J, Hessian PA,. Comparison of phenotype expression by mononuclear phagocytes within subcutaneous gouty tophi and rheumatoid nodules. Rheumatol Int 1987; 7: 187-93.
35. Feige U, Overwien B, Sorg C,. Purification of human blood monocytes by hypotonic density gradient centrifugation in Percoll. J Immunol Methods 1982; 54: 309-15.
36. Hunter MJ, Chazin WJ,. High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem 1998; 273: 12427-35.
37. Viemann D, Goebeler M, Schmid S, Klimmek K, Sorg C, Ludwig S, et al. Transcriptional profiling of IKK2/NF-κB- and p38 MAP kinase-dependent gene expression in TNF-α-stimulated primary human endothelial cells. Blood 2004; 103: 3365-73.
38. Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003; 23: 1034-43.
39. Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003; 23: 2564-76.
40. Wang GG, Calvo KR, Pasillas MP, Sykes DB, Hacker H, Kamps MP,. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods 2006; 3: 287-93.
41. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 1641-50.
42. Pritzker KP,. Articular pathology of gout, calcium pyrophosphate dihydrate and basic calcium phosphate crystal deposition arthropathies. In:, Terkeltaub E, editor. Gout and other crystal arthropathies. Philadelphia: Elsevier; 2011. p. 2-19.
43. Akahoshi T, Nagaoka T, Namai R, Sekiyama N, Kondo H,. Prevention of neutrophil apoptosis by monosodium urate crystals. Rheumatol Int 1997; 16: 231-5.
44. Joosten LA, Netea MG, Mylona E, Koenders MI, Malireddi RK, Oosting M, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010; 62: 3237-48.
45. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R,. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005; 52: 2936-46.
46. Robinson MJ, Tessier P, Poulsom R, Hogg N,. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 2002; 277: 3658-65.
47. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA,. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003; 170: 3233-42.
48. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-36.
49. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
50. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008; 155: 49-55.